NordForsk grants 10 million NOK in funding for a Nordic drug safety in pregnancy collaborative study.In March of 2017, the Nordic Pregnancy Drug Safety Studies (NorPreSS) was one of seven applications granted funding by NordForsk in their call for Nordic register-based research projects. NorPress is a collaborative project between members from the five Nordic countries: Norway, Iceland, Finland, Denmark, and the CPE at KI here in Sweden. The application was submitted under the leadership of Professor Kari Furu at the Norwegian Institute of Public Health. From CPE to work on this project are Helle Kieler, Johan Reutfors, Ingvild Odsbu, Gabriella Bröms and Pär Karlsson as well as recently joined postdoc Carolyn Cesta. The goal of NorPreSS is to investigate medication use during pregnancy (antidepressants, anti-diabetics, and anti-epileptics) and the short and long term consequences in the mother and her offspring. By combining population data, this collaboration will be in the forefront of the field of drug safety in pregnancy and will contribute to scientific innovation as well as generate important new knowledge in the field of teratogenicity of drugs and longer-term effects of drug exposure in-utero.